Analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a report released on Tuesday. The brokerage set a “sell” rating on the stock.
Bio-Path Trading Up 0.7 %
BPTH stock opened at $0.82 on Tuesday. The firm has a 50 day moving average of $0.89 and a 200-day moving average of $1.12. Bio-Path has a 12-month low of $0.59 and a 12-month high of $9.99.
Institutional Trading of Bio-Path
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent quarter. Institutional investors and hedge funds own 5.74% of the company’s stock.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Articles
- Five stocks we like better than Bio-Path
- The 3 Best Retail Stocks to Shop for in August
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Technology Stocks Explained: Here’s What to Know About Tech
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- Expert Stock Trading Psychology Tips
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
